When is crossover desirable in cancer drug trials and when is it problematic?

被引：38

作者：

Haslam, A. ^{[1
]}

Prasad, V. ^{[1
,2
,3
]}

机构：

[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol Oncol, Portland, OR 97201 USA

[2] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA

[3] Oregon Hlth & Sci Univ, Ctr Hlth Care Eth, Portland, OR 97201 USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷 / 05期

关键词：

DOUBLE-BLIND; PROSTATE-CANCER; PHASE-3; PLACEBO;

D O I：

10.1093/annonc/mdy116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1079 / 1081

页数：3

共 14 条

[1]

Agency for Healthcare Research and Quality, OUTC SIP T THER

[2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[3] Epidemiology and reporting of randomised trials published in PubMed journals [J].

Chan, AW ;

Altman, DG .

LANCET, 2005, 365 (9465) :1159-1162

[4] Crossover is not associated with faster trial accrual [J].

Chen, E. Y. ;

Prasad, V. .

ANNALS OF ONCOLOGY, 2018, 29 (03) :776-777

[5]

de Bono J, 2017, NEW ENGL J MED, V377, P1694

[6] Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study [J].

Fassnacht, Martin ;

Berruti, Alfredo ;

Baudin, Eric ;

Demeure, Michael J. ;

Gilbert, Jill ;

Haak, Harm ;

Kroiss, Matthias ;

Quinn, David I. ;

Hesseltine, Elizabeth ;

Ronchi, Cristina L. ;

Terzolo, Massimo ;

Choueiri, Toni K. ;

Poondru, Srinivasu ;

Fleege, Tanya ;

Rorig, Ramona ;

Chen, Jihong ;

Stephens, Andrew W. ;

Worden, Francis ;

Hammer, Gary D. .

LANCET ONCOLOGY, 2015, 16 (04) :426-435

[7] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer [J].

Fizazi, Karim ;

NamPhuong Tran ;

Fein, Luis ;

Matsubara, Nobuaki ;

Rodriguez-Antolin, Alfredo ;

Alekseev, Boris Y. ;

Ozguroglu, Mustafa ;

Ye, Dingwei ;

Feyerabend, Susan ;

Protheroe, Andrew ;

De Porre, Peter ;

Kheoh, Thian ;

Park, Youn C. ;

Todd, Mary B. ;

Chi, Kim N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :352-360

[8] TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALS [J].

Henshall, Chris ;

Latimer, Nicholas R. ;

Sansom, Lloyd ;

Ward, Robyn L. .

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2016, 32 (03) :167-174

[9] Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer [J].

Higano, Celestia S. ;

Schellhammer, Paul F. ;

Small, Eric J. ;

Burch, Patrick A. ;

Nemunaitis, John ;

Yuh, Lianng ;

Provost, Nicole ;

Frohlich, Mark W. .

CANCER, 2009, 115 (16) :3670-3679

[10] Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start [J].

Prasad, Vinay ;

Berger, Vance W. .

MAYO CLINIC PROCEEDINGS, 2015, 90 (09) :1171-1175

← 1 2 →